Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, systemic therapies, and more to manage symptoms.

After metabolic bariatric surgery for obesity, 69.5 percent of patients demonstrated improvement or remission of psoriasis. HealthDay News — Metabolic bariatric surgery (MBS) is associated with ...

Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

A group of researchers from the University of Erlangen-Nuremberg has discovered which immune cells migrate from the skin of ...

Psoriasis causes your body to make new skin cells too quickly. These cells tend to pile up and form spots, bumps, and thick scaly patches called plaques that can be uncomfortable. Scientists think ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...